Sandoz Paclitaxel 30 mg. 100 mg . 300 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 14 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced ovarian, breast, and non-small cell lung cancer.
Dosage (summary)
Ovarian carcinoma: 135 mg/mu00b2 + cisplatin; Breast carcinoma: 175 mg/mu00b2; Lung carcinoma: 175 mg/mu00b2, every 3 weeks.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Embryotoxic; contraindicated in pregnancy. Discontinue breastfeeding during therapy.
Key Drug Interactions
- Ketoconazole may inhibit metabolism
- Increased doxorubicin levels when combined
Contraindications
- Hypersensitivity to paclitaxel
- Neutrophil count < 1500/mmu00b3
Common side effects
- Myelosuppression
- Peripheral neuropathy
- Alopecia
- Hypotension
Counselling Points
- Pre-medicate with corticosteroids and antihistamines
- Avoid pregnancy during treatment
- Monitor for signs of hypersensitivity
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiac conduction abnormalities
Important Disclaimer
The Sandoz Paclitaxel 30 mg. 100 mg . 300 mg Concentrate for solution for infusion professional information leaflet below is the property of Sandoz Sa 1 and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
